لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

المؤلفون: Lanyon-Hogg T; 1 Department of Chemistry, Imperial College London, London, UK., Patel NV; 1 Department of Chemistry, Imperial College London, London, UK., Ritzefeld M; 1 Department of Chemistry, Imperial College London, London, UK., Boxall KJ; 2 Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, UK., Burke R; 2 Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, UK., Blagg J; 2 Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, UK., Magee AI; 3 Molecular Medicine Section, National Heart & Lung Institute, Imperial College London, London, UK., Tate EW; 1 Department of Chemistry, Imperial College London, London, UK.

المصدر: SLAS discovery : advancing life sciences R & D [SLAS Discov] 2017 Apr; Vol. 22 (4), pp. 418-424. Date of Electronic Publication: 2017 Jan 31.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: SAGE Publications Country of Publication: United States NLM ID: 101697563 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2472-5560 (Electronic) Linking ISSN: 24725552 NLM ISO Abbreviation: SLAS Discov Subsets: MEDLINE

مواضيع طبية MeSH: Protein Processing, Post-Translational*, Acyltransferases/*metabolism , Electrophoretic Mobility Shift Assay/*methods , Hedgehog Proteins/*metabolism , Microfluidics/*methods, Acyltransferases/antagonists & inhibitors ; Acyltransferases/genetics ; Amino Acid Sequence ; Electrophoretic Mobility Shift Assay/instrumentation ; Enzyme Assays ; Enzyme Inhibitors/pharmacology ; HEK293 Cells ; Hedgehog Proteins/genetics ; Humans ; Kinetics ; Lipoylation/drug effects ; Microfluidics/instrumentation ; Recombinant Proteins/genetics ; Recombinant Proteins/metabolism

المؤلفون: Osborne JD, Matthews TP, McHardy T, Proisy N, Cheung KM, Lainchbury M, Brown N, Walton MI, Eve PD, Boxall KJ, Hayes A, Henley AT, Valenti MR, De Haven Brandon AK, Box G, Jamin Y, Robinson SP, Westwood IM, van Montfort RL, Leonard PM; Sareum Ltd. , Cambridge CB22 3FX, U.K., Lamers MB; Sareum Ltd. , Cambridge CB22 3FX, U.K., Reader JC; Sareum Ltd. , Cambridge CB22 3FX, U.K., Aherne GW, Raynaud FI, Eccles SA, Garrett MD, Collins I

المصدر: Journal of medicinal chemistry [J Med Chem] 2016 Jun 09; Vol. 59 (11), pp. 5221-37. Date of Electronic Publication: 2016 May 23.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Chemical Society Country of Publication: United States NLM ID: 9716531 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1520-4804 (Electronic) Linking ISSN: 00222623 NLM ISO Abbreviation: J Med Chem Subsets: MEDLINE

مواضيع طبية MeSH: 4-Aminopyridine/*analogs & derivatives , Checkpoint Kinase 1/*antagonists & inhibitors , Protein Kinase Inhibitors/*pharmacology , Pyrazines/*pharmacology, 4-Aminopyridine/chemical synthesis ; 4-Aminopyridine/chemistry ; 4-Aminopyridine/pharmacology ; Checkpoint Kinase 1/metabolism ; Dose-Response Relationship, Drug ; Humans ; Models, Molecular ; Molecular Structure ; Protein Kinase Inhibitors/chemical synthesis ; Protein Kinase Inhibitors/chemistry ; Pyrazines/chemical synthesis ; Pyrazines/chemistry ; Structure-Activity Relationship

المؤلفون: Bavetsias V; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research , 15 Cotswold Road, London SM2 5NG, U.K., Lanigan RM; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research , 15 Cotswold Road, London SM2 5NG, U.K., Ruda GF; Structural Genomics Consortium (SGC), University of Oxford , ORCRB Roosevelt Drive, Oxford OX3 7DQ, U.K.; Target Discovery Institute (TDI), Nuffield Department of Medicine, University of Oxford , NDMRB Roosevelt Drive, Oxford OX3 7FZ, U.K., Atrash B; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research , 15 Cotswold Road, London SM2 5NG, U.K., McLaughlin MG; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research , 15 Cotswold Road, London SM2 5NG, U.K., Tumber A; Structural Genomics Consortium (SGC), University of Oxford , ORCRB Roosevelt Drive, Oxford OX3 7DQ, U.K.; Target Discovery Institute (TDI), Nuffield Department of Medicine, University of Oxford , NDMRB Roosevelt Drive, Oxford OX3 7FZ, U.K., Mok NY; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research , 15 Cotswold Road, London SM2 5NG, U.K., Le Bihan YV; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research , 15 Cotswold Road, London SM2 5NG, U.K., Dempster S; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research , 15 Cotswold Road, London SM2 5NG, U.K., Boxall KJ; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research , 15 Cotswold Road, London SM2 5NG, U.K., Jeganathan F; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research , 15 Cotswold Road, London SM2 5NG, U.K., Hatch SB; Structural Genomics Consortium (SGC), University of Oxford , ORCRB Roosevelt Drive, Oxford OX3 7DQ, U.K.; Target Discovery Institute (TDI), Nuffield Department of Medicine, University of Oxford , NDMRB Roosevelt Drive, Oxford OX3 7FZ, U.K., Savitsky P; Structural Genomics Consortium (SGC), University of Oxford , ORCRB Roosevelt Drive, Oxford OX3 7DQ, U.K., Velupillai S; Structural Genomics Consortium (SGC), University of Oxford , ORCRB Roosevelt Drive, Oxford OX3 7DQ, U.K., Krojer T; Structural Genomics Consortium (SGC), University of Oxford , ORCRB Roosevelt Drive, Oxford OX3 7DQ, U.K., England KS; Structural Genomics Consortium (SGC), University of Oxford , ORCRB Roosevelt Drive, Oxford OX3 7DQ, U.K.; Target Discovery Institute (TDI), Nuffield Department of Medicine, University of Oxford , NDMRB Roosevelt Drive, Oxford OX3 7FZ, U.K., Sejberg J; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research , 15 Cotswold Road, London SM2 5NG, U.K., Thai C; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research , 15 Cotswold Road, London SM2 5NG, U.K., Donovan A; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research , 15 Cotswold Road, London SM2 5NG, U.K., Pal A; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research , 15 Cotswold Road, London SM2 5NG, U.K., Scozzafava G; Structural Genomics Consortium (SGC), University of Oxford , ORCRB Roosevelt Drive, Oxford OX3 7DQ, U.K.; Target Discovery Institute (TDI), Nuffield Department of Medicine, University of Oxford , NDMRB Roosevelt Drive, Oxford OX3 7FZ, U.K., Bennett JM; Structural Genomics Consortium (SGC), University of Oxford , ORCRB Roosevelt Drive, Oxford OX3 7DQ, U.K.; Target Discovery Institute (TDI), Nuffield Department of Medicine, University of Oxford , NDMRB Roosevelt Drive, Oxford OX3 7FZ, U.K., Kawamura A; Chemistry Research Laboratory, University of Oxford , Mansfield Road, Oxford OX1 3TA, U.K., Johansson C; Structural Genomics Consortium (SGC), University of Oxford , ORCRB Roosevelt Drive, Oxford OX3 7DQ, U.K.; Botnar Research Centre, NIHR Oxford Biomedical Research Unit , Oxford OX3 7LD, U.K., Szykowska A; Structural Genomics Consortium (SGC), University of Oxford , ORCRB Roosevelt Drive, Oxford OX3 7DQ, U.K., Gileadi C; Structural Genomics Consortium (SGC), University of Oxford , ORCRB Roosevelt Drive, Oxford OX3 7DQ, U.K., Burgess-Brown NA; Structural Genomics Consortium (SGC), University of Oxford , ORCRB Roosevelt Drive, Oxford OX3 7DQ, U.K., von Delft F; Structural Genomics Consortium (SGC), University of Oxford , ORCRB Roosevelt Drive, Oxford OX3 7DQ, U.K.; Diamond Light Source (DLS), Harwell Science and Innovation Campus , Didcot OX11 0DE, U.K.; Department of Biochemistry, University of Johannesburg , Auckland Park 2006, South Africa., Oppermann U; Structural Genomics Consortium (SGC), University of Oxford , ORCRB Roosevelt Drive, Oxford OX3 7DQ, U.K.; Botnar Research Centre, NIHR Oxford Biomedical Research Unit , Oxford OX3 7LD, U.K., Walters Z; Divisions of Molecular Pathology and Cancer Therapeutics, The Institute of Cancer Research , London SM2 5NG, U.K., Shipley J; Divisions of Molecular Pathology and Cancer Therapeutics, The Institute of Cancer Research , London SM2 5NG, U.K., Raynaud FI; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research , 15 Cotswold Road, London SM2 5NG, U.K., Westaway SM; Epinova Discovery Performance Unit, Medicines Research Centre, GlaxoSmithKline R&D , Stevenage SG1 2NY, U.K., Prinjha RK; Epinova Discovery Performance Unit, Medicines Research Centre, GlaxoSmithKline R&D , Stevenage SG1 2NY, U.K., Fedorov O; Structural Genomics Consortium (SGC), University of Oxford , ORCRB Roosevelt Drive, Oxford OX3 7DQ, U.K.; Target Discovery Institute (TDI), Nuffield Department of Medicine, University of Oxford , NDMRB Roosevelt Drive, Oxford OX3 7FZ, U.K., Burke R; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research , 15 Cotswold Road, London SM2 5NG, U.K., Schofield CJ; Chemistry Research Laboratory, University of Oxford , Mansfield Road, Oxford OX1 3TA, U.K., Westwood IM; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research , 15 Cotswold Road, London SM2 5NG, U.K., Bountra C; Structural Genomics Consortium (SGC), University of Oxford , ORCRB Roosevelt Drive, Oxford OX3 7DQ, U.K., Müller S; Structural Genomics Consortium (SGC), University of Oxford , ORCRB Roosevelt Drive, Oxford OX3 7DQ, U.K.; Target Discovery Institute (TDI), Nuffield Department of Medicine, University of Oxford , NDMRB Roosevelt Drive, Oxford OX3 7FZ, U.K., van Montfort RL; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research , 15 Cotswold Road, London SM2 5NG, U.K., Brennan PE; Structural Genomics Consortium (SGC), University of Oxford , ORCRB Roosevelt Drive, Oxford OX3 7DQ, U.K.; Target Discovery Institute (TDI), Nuffield Department of Medicine, University of Oxford , NDMRB Roosevelt Drive, Oxford OX3 7FZ, U.K., Blagg J; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research , 15 Cotswold Road, London SM2 5NG, U.K.

المصدر: Journal of medicinal chemistry [J Med Chem] 2016 Feb 25; Vol. 59 (4), pp. 1388-409. Date of Electronic Publication: 2016 Jan 07.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Chemical Society Country of Publication: United States NLM ID: 9716531 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1520-4804 (Electronic) Linking ISSN: 00222623 NLM ISO Abbreviation: J Med Chem Subsets: MEDLINE

مواضيع طبية MeSH: Enzyme Inhibitors/*chemistry , Enzyme Inhibitors/*pharmacology , Jumonji Domain-Containing Histone Demethylases/*antagonists & inhibitors , Nuclear Proteins/*antagonists & inhibitors , Pyrimidinones/*chemistry , Pyrimidinones/*pharmacology , Repressor Proteins/*antagonists & inhibitors, Caco-2 Cells ; Cell Membrane Permeability ; Enzyme Inhibitors/pharmacokinetics ; Humans ; Jumonji Domain-Containing Histone Demethylases/chemistry ; Jumonji Domain-Containing Histone Demethylases/metabolism ; Nuclear Proteins/chemistry ; Nuclear Proteins/metabolism ; Pyrimidinones/pharmacokinetics ; Repressor Proteins/chemistry ; Repressor Proteins/metabolism

المؤلفون: Walton MI; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Eve PD; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Hayes A; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Henley AT; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Valenti MR; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., De Haven Brandon AK; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Box G; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Boxall KJ; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Tall M; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Swales K; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Matthews TP; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., McHardy T; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Lainchbury M; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Osborne J; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Hunter JE; Institute for Cell and Molecular Biosciences, Medical School, Newcastle University, Newcastle Upon Tyne, UK., Perkins ND; Institute for Cell and Molecular Biosciences, Medical School, Newcastle University, Newcastle Upon Tyne, UK., Aherne GW; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Reader JC; Sareum Ltd, Cambridge, UK., Raynaud FI; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Eccles SA; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Collins I; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Garrett MD; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.; School of Biosciences, University of Kent, Canterbury, Kent, UK.

المصدر: Oncotarget [Oncotarget] 2016 Jan 19; Vol. 7 (3), pp. 2329-42.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Impact Journals Country of Publication: United States NLM ID: 101532965 Publication Model: Print Cited Medium: Internet ISSN: 1949-2553 (Electronic) Linking ISSN: 19492553 NLM ISO Abbreviation: Oncotarget Subsets: MEDLINE

مواضيع طبية MeSH: Xenograft Model Antitumor Assays*, 4-Aminopyridine/*analogs & derivatives , Carcinoma, Non-Small-Cell Lung/*drug therapy , Checkpoint Kinase 1/*drug effects , Lung Neoplasms/*drug therapy , Lymphoma, B-Cell/*drug therapy , Proto-Oncogene Proteins c-myc/*genetics , Proto-Oncogene Proteins p21(ras)/*genetics , Pyrazines/*pharmacology, 4-Aminopyridine/pharmacokinetics ; 4-Aminopyridine/pharmacology ; Animals ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Apoptosis/drug effects ; CDC2 Protein Kinase ; Camptothecin/analogs & derivatives ; Camptothecin/pharmacology ; Cell Cycle Checkpoints/drug effects ; Cell Line, Tumor ; Checkpoint Kinase 1/metabolism ; Checkpoint Kinase 2/antagonists & inhibitors ; Cyclin-Dependent Kinases/antagonists & inhibitors ; DNA Damage/drug effects ; Deoxycytidine/analogs & derivatives ; Deoxycytidine/pharmacology ; Drug Synergism ; HT29 Cells ; Humans ; Irinotecan ; Mice ; Mice, Inbred BALB C ; Mice, Nude ; Mice, Transgenic ; Pyrazines/pharmacokinetics ; Gemcitabine

المؤلفون: Bavetsias V; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research , London SM2 5NG, United Kingdom., Faisal A, Crumpler S, Brown N, Kosmopoulou M, Joshi A, Atrash B, Pérez-Fuertes Y, Schmitt JA, Boxall KJ, Burke R, Sun C, Avery S, Bush K, Henley A, Raynaud FI, Workman P, Bayliss R, Linardopoulos S, Blagg J

المصدر: Journal of medicinal chemistry [J Med Chem] 2013 Nov 27; Vol. 56 (22), pp. 9122-35. Date of Electronic Publication: 2013 Nov 06.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Chemical Society Country of Publication: United States NLM ID: 9716531 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1520-4804 (Electronic) Linking ISSN: 00222623 NLM ISO Abbreviation: J Med Chem Subsets: MEDLINE

مواضيع طبية MeSH: Drug Design*, Aurora Kinase A/*antagonists & inhibitors , Aurora Kinase B/*antagonists & inhibitors , Imidazoles/*chemistry , Imidazoles/*pharmacology , Protein Kinase Inhibitors/*chemistry , Protein Kinase Inhibitors/*pharmacology, Animals ; Aurora Kinase A/chemistry ; Aurora Kinase A/metabolism ; Aurora Kinase B/chemistry ; Aurora Kinase B/metabolism ; Catalytic Domain ; Drug Stability ; HCT116 Cells ; Humans ; Imidazoles/metabolism ; Indoles/chemistry ; Indoles/metabolism ; Indoles/pharmacology ; Isoenzymes/antagonists & inhibitors ; Isoenzymes/chemistry ; Isoenzymes/metabolism ; Male ; Mice ; Molecular Docking Simulation ; Protein Kinase Inhibitors/metabolism ; Substrate Specificity

المؤلفون: Lainchbury M; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, 15 Cotswold Road, Sutton, SM2 5NG U. K., Matthews TP, McHardy T, Boxall KJ, Walton MI, Eve PD, Hayes A, Valenti MR, de Haven Brandon AK, Box G, Aherne GW, Reader JC, Raynaud FI, Eccles SA, Garrett MD, Collins I

المصدر: Journal of medicinal chemistry [J Med Chem] 2012 Nov 26; Vol. 55 (22), pp. 10229-40. Date of Electronic Publication: 2012 Oct 19.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Chemical Society Country of Publication: United States NLM ID: 9716531 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1520-4804 (Electronic) Linking ISSN: 00222623 NLM ISO Abbreviation: J Med Chem Subsets: MEDLINE

مواضيع طبية MeSH: Aminopyridines/*pharmacology , Antineoplastic Agents/*pharmacology , Colonic Neoplasms/*drug therapy , Neuroblastoma/*drug therapy , Protein Kinase Inhibitors/*pharmacology , Protein Kinases/*chemistry , Pyrimidines/*pharmacology, Administration, Oral ; Aminopyridines/chemical synthesis ; Animals ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/chemical synthesis ; Checkpoint Kinase 1 ; Child ; Colonic Neoplasms/enzymology ; DNA Damage/drug effects ; Drug Design ; Humans ; Mice ; Mice, Nude ; Mice, Transgenic ; N-Myc Proto-Oncogene Protein ; Neuroblastoma/enzymology ; Nuclear Proteins/genetics ; Oncogene Proteins/genetics ; Protein Kinase Inhibitors/administration & dosage ; Protein Kinase Inhibitors/chemical synthesis ; Protein Kinases/metabolism ; Pyrimidines/chemical synthesis ; Tumor Cells, Cultured ; Xenograft Model Antitumor Assays

المؤلفون: Walton MI; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, Sutton, United Kingdom. Mike.Walton@icr.ac.uk, Eve PD, Hayes A, Valenti MR, De Haven Brandon AK, Box G, Hallsworth A, Smith EL, Boxall KJ, Lainchbury M, Matthews TP, Jamin Y, Robinson SP, Aherne GW, Reader JC, Chesler L, Raynaud FI, Eccles SA, Collins I, Garrett MD

المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2012 Oct 15; Vol. 18 (20), pp. 5650-61. Date of Electronic Publication: 2012 Aug 28.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: Neoplasms, Experimental*/drug therapy , Neoplasms, Experimental*/metabolism , Neuroblastoma*/drug therapy , Neuroblastoma*/metabolism , Protein Kinases*/genetics , Protein Kinases*/metabolism, Aminopyridines/*administration & dosage , Pyrimidines/*administration & dosage, Administration, Oral ; Animals ; Antineoplastic Agents/administration & dosage ; Biomarkers, Tumor/genetics ; Biomarkers, Tumor/metabolism ; Cell Cycle Checkpoints/drug effects ; Checkpoint Kinase 1 ; Gene Expression Regulation, Neoplastic/drug effects ; Humans ; Mice ; Mice, Transgenic ; Protein Kinase Inhibitors/administration & dosage

المؤلفون: Anderson VE; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, Sutton, Surrey, United Kingdom., Walton MI, Eve PD, Boxall KJ, Antoni L, Caldwell JJ, Aherne W, Pearl LH, Oliver AW, Collins I, Garrett MD

المصدر: Cancer research [Cancer Res] 2011 Jan 15; Vol. 71 (2), pp. 463-72.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 2984705R Publication Model: Print Cited Medium: Internet ISSN: 1538-7445 (Electronic) Linking ISSN: 00085472 NLM ISO Abbreviation: Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: Poly(ADP-ribose) Polymerase Inhibitors*, Antineoplastic Combined Chemotherapy Protocols/*pharmacology , Protein Serine-Threonine Kinases/*antagonists & inhibitors , Quinazolines/*pharmacology, Bleomycin/administration & dosage ; Cell Cycle/drug effects ; Cell Line, Tumor ; Checkpoint Kinase 2 ; Crystallography, X-Ray ; Drug Synergism ; Enzyme Activation/drug effects ; HCT116 Cells ; HT29 Cells ; HeLa Cells ; Heterocyclic Compounds, 3-Ring/administration & dosage ; Heterocyclic Compounds, 3-Ring/pharmacology ; Humans ; Models, Molecular ; Protein Serine-Threonine Kinases/chemistry ; Protein Serine-Threonine Kinases/metabolism ; Quinazolines/administration & dosage ; Quinazolines/chemistry

المؤلفون: Walton MI; Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Surrey, United Kingdom. Mike.Walton@icr.ac.uk, Eve PD, Hayes A, Valenti M, De Haven Brandon A, Box G, Boxall KJ, Aherne GW, Eccles SA, Raynaud FI, Williams DH, Reader JC, Collins I, Garrett MD

المصدر: Molecular cancer therapeutics [Mol Cancer Ther] 2010 Jan; Vol. 9 (1), pp. 89-100. Date of Electronic Publication: 2010 Jan 06.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Association for Cancer Research, Inc Country of Publication: United States NLM ID: 101132535 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1538-8514 (Electronic) Linking ISSN: 15357163 NLM ISO Abbreviation: Mol Cancer Ther Subsets: MEDLINE

مواضيع طبية MeSH: Xenograft Model Antitumor Assays*, Isoquinolines/*pharmacology , Protein Kinase Inhibitors/*pharmacology , Protein Kinases/*metabolism , Pyrazines/*pharmacology, Animals ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/pharmacology ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Biomarkers, Tumor/metabolism ; Camptothecin/administration & dosage ; Camptothecin/analogs & derivatives ; Camptothecin/pharmacology ; Cell Death/drug effects ; Cell Line, Tumor ; Checkpoint Kinase 1 ; DNA Damage ; Deoxycytidine/administration & dosage ; Deoxycytidine/analogs & derivatives ; Deoxycytidine/pharmacology ; Drug Synergism ; G2 Phase/drug effects ; Humans ; Irinotecan ; Isoquinolines/administration & dosage ; Isoquinolines/chemistry ; Isoquinolines/pharmacokinetics ; Mice ; Mice, Nude ; Mutagens/toxicity ; Phosphorylation/drug effects ; Protein Kinase Inhibitors/administration & dosage ; Protein Kinase Inhibitors/chemistry ; Protein Kinase Inhibitors/pharmacokinetics ; Pyrazines/administration & dosage ; Pyrazines/chemistry ; Pyrazines/pharmacokinetics ; Gemcitabine